14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
CRMD vs TLPH: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 16, 2026, Talphera, Inc. (TLPH) captures the overall head-to-head institutional edge over CorMedix Inc. (CRMD) on higher Unified Composite conviction (37.1/100 SELL vs. 53.2/100 HOLD) after splitting the core matrix 5–5 (led by Valuation Multiples, Options & Positioning), while CRMD wins 4–2 across the 6-pillar growth and valuation breakdown. CRMD trades at $4.92 (49.0x Forward P/E, 41.0% operating margin) versus TLPH at $0.86 (1.0x Forward P/E, -1474700.0% operating margin).
Composite vs. Pillar Nuance: While CRMD currently prints a higher short-term Unified Composite Score (53.2/100 HOLD vs. TLPH 37.1/100 SELL), TLPH captures the overall institutional head-to-head verdict (5–5 matrix metrics and 2–4 across the 6 pillars) due to superior fundamental profitability (-1474700.0% vs. 41.0% operating margin) and revenue trajectory (+0.0% vs. -47.7% YoY).
Technical & Structure Timing Caution: CRMD is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 29.3); meanwhile TLPH is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 26.1). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on CRMD vs TLPH. Trailing 12-month operating profitability (CRMD 41.0% vs TLPH -1474700.0%) and valuation multiples (CRMD 49.0x vs TLPH 1.0x Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Drug Manufacturers - Specialty & Generic value chain with $53.7M market capitalization and -1474700.0% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ CRMD vs TLPH Key Questions & Quantitative Answers
As of Nov 16, 2026, Talphera, Inc. (TLPH) captures the overall head-to-head institutional edge over CorMedix Inc. (CRMD) on higher Unified Composite conviction (37.1/100 SELL vs. 53.2/100 HOLD) after splitting the core matrix 5–5 (led by Valuation Multiples, Options & Positioning), while CRMD wins 4–2 across the 6-pillar growth and valuation breakdown. CRMD trades at $4.92 (49.0x Forward P/E, 41.0% operating margin) versus TLPH at $0.86 (1.0x Forward P/E, -1474700.0% operating margin). Composite vs. Pillar Nuance: While CRMD currently prints a higher short-term Unified Composite Score (53.2/100 HOLD vs. TLPH 37.1/100 SELL), TLPH captures the overall institutional head-to-head verdict (5–5 matrix metrics and 2–4 across the 6 pillars) due to superior fundamental profitability (-1474700.0% vs. 41.0% operating margin) and revenue trajectory (+0.0% vs. -47.7% YoY). Technical & Structure Timing Caution: CRMD is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 29.3); meanwhile TLPH is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 26.1). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
CRMD leads the Growth & Scale pillar: CRMD posts -47.7% YoY revenue growth and +6.7% YoY earnings growth on $1.05B TTM revenue (87.4% gross margin, 41.0% operating margin), compared with TLPH at +0.0% YoY revenue growth and +0.0% YoY earnings growth on $1,000 TTM revenue (N/A gross margin, -1474700.0% operating margin). On trailing 12-month operating scale, CRMD generates $1.05B in USD-normalized revenue versus $1,000 for TLPH. In operating R&D and SG&A reinvestment, CRMD deploys 46.4% of Rev ($488M) (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for TLPH.
TLPH screens cheaper on headline valuation multiples. CRMD trades at 49.0x Forward P/E, 2.4x Trailing P/E, 3.79x PEG, and N/M EV/Revenue (74.6% FCF margin), whereas TLPH trades at 1.0x Forward P/E, 1.0x Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against CRMD (15.3% ROE) versus TLPH (-143.4% ROE) capital efficiency.
In options market volatility and institutional positioning, CRMD carries 56.3% implied volatility (25th %ile, Compressed (<25th %ile)), a 0.69x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (1.20β · 107% Vol realized risk). By comparison, TLPH carries 118.4% implied volatility (100th %ile, Extreme (>80th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.11β · 58% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.